Parapharmacity
InactiveInactive since 25-06-2026; last annual accounts for fiscal year 2025.
Signals
Two signals. The signal on the left, the evidence on the right.
+raises risk○neutral
raises risk · Negative equity
The 2025 annual accounts show negative equity and a net loss.
NBB · annual accounts 2025Equity per financial year
1819202122232425
2018 to 2025 · latest year -€176,527
neutral · Latest accounts filed on time
The financial year that closed on 31-12-2025 was due by 31-07-2026 and was filed on 30-06-2026, 31 days ahead of the deadline.
NBB · 10 filingsDeviation from the deadline
2025
31 d early
2024
30 d early
2023
15 d early
2022
31 d late
2021
242 d late
2020
240 d late
2019
140 d late
← before the deadline
after the deadline →
tick = median of all Belgian filingsring = median in the sector
This company filed its last 7 accounts on average 82 days after the deadline; the sector median for financial year 2024 is on the deadline day, and 46% of the sector filed late.
Checked, nothing found (1)
History
Go further with this company
Who ran this company, and where was it based, on a date before the end?Company as of a date Which other companies belong to the same group?CAPNOR · 26 companies How is the Retail sale of pharmaceutical products sector doing?Sector figures
Investigating this company? Keep it with today's facts in a case file.
Financials · fiscal year 2025, abbreviated schema
Turnover
Not included in this filing
EBIT margin
Not included in this filing
Net result
-€11,676
2024 · €18,427
Working capital
-€176,527▼ 7.1%
2024 · -€164,851
Trend over the years
Click a name to add, emphasise or remove a line.Band: the middle half (P25 to P75) of NACE 47, Retail trade, each year against the same schema; no band under 30 filings. Dashed line: the median.
Every figure with its change against the fiscal year before
favourable
unfavourable
Line20212022202320242025
Operating result-€325,786-€139,565▲ 57.2%€123,473€44,160▼ 64.2%-€1,092
Net result-€331,356below the sector's middle half-€135,390below the sector's middle half▲ 59.1%€116,179within the sector's middle half€18,427within the sector's middle half▼ 84.1%-€11,676below the sector's middle half
Equity-€164,066below the sector's middle half-€299,456below the sector's middle half▼ 82.5%-€183,278below the sector's middle half▲ 38.8%-€164,851below the sector's middle half▲ 10.1%-€176,527below the sector's middle half▼ 7.1%
Total assets€4.3mabove the sector's middle half▲ 1,940%€1.6mwithin the sector's middle half▼ 62.8%€3.2mabove the sector's middle half▲ 105%€2.9mabove the sector's middle half▼ 10.5%€2.8mabove the sector's middle half▼ 4.0%
Debt€4.3m▲ 10,381%€1.9m▼ 56.7%€3.4m▲ 82.0%€3.1m▼ 10.5%€3.0m▼ 3.4%
Working capital-€459,030below the sector's middle half-€502,071below the sector's middle half▼ 9.4%-€321,901below the sector's middle half▲ 35.9%-€164,851below the sector's middle half▲ 48.8%-€176,527below the sector's middle half▼ 7.1%
Solvency-3.9%below the sector's middle half▼ 84.0pp-18.9%below the sector's middle half▼ 15.1pp-5.7%below the sector's middle half▲ 13.3pp-5.7%below the sector's middle half=-6.3%below the sector's middle half▼ 0.7pp
Current ratio0.89below the sector's middle half▼ 4.140.73below the sector's middle half▼ 0.160.91below the sector's middle half▲ 0.170.95below the sector's middle half▲ 0.040.94below the sector's middle half▼ 0.01
Return on assets (ROA)-7.8%below the sector's middle half▼ 30.0pp-8.5%below the sector's middle half▼ 0.8pp3.6%within the sector's middle half▲ 12.1pp0.6%within the sector's middle half▼ 2.9pp-0.4%below the sector's middle half▼ 1.1pp
Staff (FTE)18.3above the sector's middle half13.4within the sector's middle half▼ 26.8%9.6within the sector's middle half▼ 28.4%7.1within the sector's middle half▼ 26.0%1.1below the sector's middle half▼ 84.5%
above
within
below
the middle half (P25 to P75) of NACE 47, Retail trade, each year against the same schema; no band under 30 filings.
Why a figure moved sharply
- 2025 Staff (FTE) -85% on 2024. The accounts now follow the abbreviated schema, last year the full schema.
Result per fiscal year
Operating resultNet result
The operating result turns negative in 2025: a loss of €1,092 after €44,160 in 2024.
Key figures and ratios
EBITDA
-€1,092▼
2024 · €78,220
Cash flow
-€11,676▼
2024 · €52,487
Debt to equity
-16.78▲
2024 · -18.61
Interest coverage
-0.01▼
2024 · 0.59
Debt ≤ 1 year
€3.0m▼
2024 · €3.1m
Staff costs
€12,418▼
2024 · €335,277
Green means a favourable move, even when the figure itself falls: as with debt or debt to equity.
Annual accounts
| Line | 2021 | 2022 | 2023 | 2024 | 2025 | Change |
|---|---|---|---|---|---|---|
| Non-recurring operating income76A | €12,505 | €0 | €21,297 | €0 | €118 | - |
| Remuneration, social security and pensions62 | €696,122 | €532,566 | €354,957 | €335,277 | €12,418 | ▼ 96.3% |
| Depreciation of and write-downs on formation expenses, intangible and tangible fixed assets630 | €74,244 | €53,017 | €40,860 | €34,060 | €0 | ▼ 100% |
| Write-downs on stocks, contracts in progress and trade receivables: additions (reversals)631/4 | €5,779 | -€4,488 | -€615 | -€677 | €0 | ▲ 100% |
| Provisions for liabilities and charges: additions (uses and reversals)635/8 | €77,000 | -€77,000 | €0 | - | - | - |
| Other operating charges640/8 | €11,635 | €44,464 | €88,193 | €1,134 | €9,600 | ▲ 746% |
| Non-recurring operating charges66A | €1,019 | €8,472 | €347 | €35,774 | €0 | ▼ 100% |
| Gross operating margin9900 | €540,014 | €417,467 | €607,216 | €449,728 | €20,926 | ▼ 95.3% |
| Operating profit (loss)9901 | -€325,786 | -€139,565 | €123,473 | €44,160 | -€1,092 | ▼ 102% |
| Financial income75/76B | €3,332 | €29,420 | €77,547 | €105,784 | €86,093 | ▼ 18.6% |
| Recurring financial income75 | €3,332 | €29,420 | €77,547 | €105,784 | €86,093 | ▼ 18.6% |
| Financial charges65/66B | €8,903 | €25,275 | €84,841 | €131,516 | €96,677 | ▼ 26.5% |
| Recurring financial charges65 | €8,903 | €25,275 | €84,841 | €131,516 | €96,677 | ▼ 26.5% |
| Profit (loss) for the period before taxes9903 | -€331,356 | -€135,420 | €116,179 | €18,427 | -€11,676 | ▼ 163% |
| Income taxes67/77 | €0 | -€30 | €0 | - | - | - |
| Profit (loss) for the period9904 | -€331,356 | -€135,390 | €116,179 | €18,427 | -€11,676 | ▼ 163% |
| Profit (loss) for the period to be appropriated9905 | -€331,356 | -€135,390 | €116,179 | €18,427 | -€11,676 | ▼ 163% |
| Line | 2021 | 2022 | 2023 | 2024 | 2025 | Change |
|---|---|---|---|---|---|---|
| Assets | ||||||
| Total assets20/58 | €4.3m | €1.6m | €3.2m | €2.9m | €2.8m | ▼ 4.0% |
| Formation expenses20 | €66 | €48 | €30 | €0 | - | - |
| Fixed assets21/28 | €371,898 | €202,567 | €138,594 | €0 | - | - |
| Intangible fixed assets21 | €55,048 | €41,928 | €28,530 | €0 | - | - |
| Tangible fixed assets22/27 | €115,102 | €132,639 | €82,063 | €0 | - | - |
| Furniture and vehicles24 | €26,923 | €17,938 | €41,745 | €0 | - | - |
| Other tangible fixed assets26 | €88,179 | €64,833 | €40,319 | €0 | - | - |
| Assets under construction and advance payments27 | - | €49,867 | €0 | - | - | - |
| Financial fixed assets28 | €201,749 | €28,000 | €28,000 | €0 | - | - |
| Current assets29/58 | €3.9m | €1.4m | €3.1m | €2.9m | €2.8m | ▼ 4.0% |
| Stocks and contracts in progress3 | €525,999 | €440,419 | €227,880 | €0 | - | - |
| Stocks30/36 | €525,999 | €440,419 | €227,880 | €0 | - | - |
| Amounts receivable within one year40/41 | €3.3m | €878,262 | €2.8m | €2.9m | €2.8m | ▼ 3.8% |
| Trade receivables40 | €750,059 | €339,625 | €295,530 | €353,637 | €99,388 | ▼ 71.9% |
| Other amounts receivable41 | €2.5m | €538,637 | €2.5m | €2.5m | €2.7m | ▲ 5.7% |
| Cash at bank and in hand54/58 | €40,217 | €62,388 | €75,027 | €3,265 | €38 | ▼ 98.8% |
| Deferred charges and accrued income490/1 | €36,597 | €0 | €4,207 | €3,059 | €0 | ▼ 100% |
| Equity and liabilities | ||||||
| Total equity and liabilities10/49 | €4.3m | €1.6m | €3.2m | €2.9m | €2.8m | ▼ 4.0% |
| Equity10/15 | -€164,066 | -€299,456 | -€183,278 | -€164,851 | -€176,527 | ▼ 7.1% |
| Contributions10/11 | €18,592 | €18,592 | €18,592 | €18,592 | €18,592 | = |
| Reserves13 | €1,859 | €1,859 | €1,859 | €1,859 | €1,859 | = |
| Non-distributable reserves130/1 | €0 | - | - | - | - | - |
| Reserves not available under the articles1311 | €0 | - | - | - | - | - |
| Distributable reserves133 | €1,859 | €1,859 | €1,859 | €1,859 | €1,859 | = |
| Profit (loss) carried forward14 | -€184,518 | -€319,908 | -€203,729 | -€185,302 | -€196,978 | ▼ 6.3% |
| Provisions and deferred taxes16 | €77,000 | €0 | - | - | - | - |
| Provisions for liabilities and charges160/5 | €77,000 | €0 | - | - | - | - |
| Other liabilities and charges164/5 | €77,000 | €0 | - | - | - | - |
| Amounts payable17/49 | €4.3m | €1.9m | €3.4m | €3.1m | €3.0m | ▼ 3.4% |
| Amounts payable within one year42/48 | €4.3m | €1.9m | €3.4m | €3.1m | €3.0m | ▼ 3.4% |
| Financial debts43 | - | - | €500,000 | €500,000 | €6,295 | ▼ 98.7% |
| Credit institutions430/8 | - | - | €500,000 | €500,000 | €6,295 | ▼ 98.7% |
| Trade debts44 | €3.6m | €531,449 | €855,017 | €134,710 | €66,150 | ▼ 50.9% |
| Suppliers440/4 | €3.6m | €531,449 | €855,017 | €134,710 | €66,150 | ▼ 50.9% |
| Advances received on contracts in progress46 | €3,074 | €5,974 | €0 | €1,490 | €0 | ▼ 100% |
| Taxes, remuneration and social security45 | €104,325 | €70,779 | €46,918 | €33,353 | €323 | ▼ 99.0% |
| Taxes450/3 | €17,800 | €17 | €0 | - | - | - |
| Remuneration and social security454/9 | €86,525 | €70,762 | €46,918 | €33,353 | €323 | ▼ 99.0% |
| Other amounts payable47/48 | €679,884 | €1.3m | €2.0m | €2.4m | €2.9m | ▲ 20.5% |
| Line | 2021 | 2022 | 2023 | 2024 | 2025 | Change |
|---|---|---|---|---|---|---|
| Profit (loss) for the period9904 | -€331,356 | -€135,390 | €116,179 | €18,427 | -€11,676 | ▼ 163% |
| + Depreciation and write-downs630 | €74,244 | €53,017 | €40,860 | €34,060 | €0 | ▼ 100% |
| Operating cash flow (approximation) | -€257,112 | -€82,373 | €157,039 | €52,487 | -€11,676 | ▼ 122% |
| Investment in fixed assets (approximation) | - | €116,314 | €23,113 | €104,534 | - | - |
| Change in cash | - | €22,171 | €12,639 | -€71,762 | -€3,227 | ▲ 95.5% |
Simplified and derived: a Belgian filing has no cash-flow statement, so these rows come from the income statement and the balance-sheet moves.
Timeline · acts, filings and financial milestones
Next filing, fiscal year 2026, expected by
2026
02-07
State Gazette act
Resignations & appointments · Restructuring · End & cessationMerger · Shareholding · Share cancellation8 facts ▸
State Gazette act
Resignations & appointments · Restructuring · End & cessation
Merger · Shareholding · Share cancellation8 facts ▸
- General meeting, 16-06-2026
- Merger, opération assimilée à la fusion par absorption, comptes annuels clôturés au 31 décembre 2025
- Shareholding, PHARMACLIC ASSETS
- Share cancellation, actions de la société absorbée, article 12:57 du Code des sociétés et des associations
- Other statement, absence de biens immobiliers et droits de propriété intellectuelle
- Declaration, absence de gage sur les actions, les actions de la société absorbée n'ont pas été données en gage
- Other statement, examen du projet commun d'opération assimilée à la fusion par absorption, aucune remarque sur le projet
- Other statement, confirmation de la décision de ne pas faire établir d'état comptable intermédiaire, confirmation de la décision de ne pas faire établir d'état comptable intermé…
30-06
NBB filing
Annual accounts filed
fiscal year 2025 · abbreviated schema
2025
01-07
NBB filing
Annual accounts filed
fiscal year 2024 · full schema
2024
16-07
NBB filing
Annual accounts filed
fiscal year 2023 · full schema
2023
31-12
Financial
Back to profitnet €116,179
Net result €116,179 after 2 loss-making years.
31-08
NBB filing
Annual accounts filed
fiscal year 2022 · full schema · 31 days late
30-03
NBB filing
Annual accounts filed
fiscal year 2021 · full schema · 242 days late
2022
28-03
NBB filing
Annual accounts filed
fiscal year 2020 · full schema · 240 days late
2021
31-12
Financial
Weakest financial yearnet -€331,356
Net result drops to -€331,356, the lowest in the series.
2020
31-12
Financial
Equity above €150,000Eq €167,290 ▲38.3%
2 profitable years in a row build equity to €167,290.
18-12
NBB filing
Annual accounts filed
fiscal year 2019 · full schema · 140 days late
2019
31-12
Financial
Back to profitnet €22,974
Net result €22,974 after one loss-making year.
Show earlier events
31-12
Financial
Equity above €100,000Eq €120,920 ▲23.5%
Equity rises from €97,947 to €120,920.
18-07
NBB filing
Annual accounts filed
fiscal year 2018 · full schema
2018
12-07
NBB filing
Annual accounts filed
fiscal year 2017 · full schema
2017
23-06
NBB filing
Annual accounts filed
fiscal year 2016 · micro schema
Financial milestoneState Gazette actNBB filingFinancial milestones sit on the fiscal year-end date, not the filing date.
1 of 10 acts read
About the unread acts
Of the 10 Belgian State Gazette acts we know for this company, 1 has been read. The other 9 have not been read yet: what they contain is neither established nor disproved here.
Have them read with priority
Sign in to place this company at the front of the reading queue.
Directors · office · real estate
Directors
10 acts for this company are in the Belgian State Gazette, of which we have read 1. We have therefore not extracted its directors from those acts yet.
Location & real-estate footprint
Registered office, Evere
Ground area
1,864 m²
Building footprint
822 m²
Volume, LiDAR
6,688 m³
Parcel 21372C0076/00H005, Brussels · tallest building 20.4 m, ±3 floors. Linked by address, not a title deed.
8
companies at this address
See who is registered here
1 parcel
Brussels
1
(100%)
| Parcel (capakey) | Region | Area | Buildings | Height / fl. |
|---|---|---|---|---|
| 21372C0076/00H005 | Brussels | 1,864 m² | 1 · 822 m² | 20.4 m · 3 fl. |
Linked by address, not proof of ownership
Good to know
1 of 1 parcel with an exact address match; the rest are indicative.
Linked through address data, this is not proof of ownership.
Articles of association
Accounting effect
01-01-2026
Custody of records
Siège de la société absorbante, société absorbante
Merger
One provision in the deed
Other statement
Prise d'effet de l'opération, décision concordante de fusion prise par la société absorbante « PHARMACLIC ASSETS »
Prendre tous engagements au nom de la société, faire telles déclarations qu'il y aura lieu, signer tous documents et en général faire tout ce qui sera utile ou…
Fin du mandat de l'administrateur et du commissaire de la société absorbée, lors de la réalisation de l'opération assimilée à la fusion par absorption
Power of attorney
One provision in the deed
Structure & network
Part of the group
CAPNOR
26 companies
Group, risk and exposure
Owners and holdings
1 ownerChain of control
- CAPNOR
- CAPNOR II
- CAPNOR II MidCo
- Medi-Market Group
- PHARMACLIC ASSETS
- Parapharmacity
Highest known parent: CAPNOR. The sources do not say who stands above it.
Owners 1
-
100%
Holdings 0
The accounts to 31-12-2025 list no holdings, and no other source names one.
According to the 2025 annual accounts of Parapharmacity and those of the other companies, the acts in the Belgian Gazette and the LEI register. The register of ultimate beneficial owners (UBO) is not public: who ultimately stands behind a natural person or a foreign parent is not stated here. A company that does not fill in these statements, or need not, is missing.
Connections & network
No current directors or connected companies found in the register.
Acquisitions and mergers
1 transactionTaken over by:PHARMACLIC ASSETS
Similar companies · same sector, comparable size
APOTHEEK VAN OVERLOOP
BE 0412.571.583
Sint-Niklaas · FTE 1.1
BRIDER
BE 0413.764.485
Geel · FTE 1.1
Apham
BE 0414.244.042
Antwerpen · FTE 1.1
APOTHEEK GODELAINE
BE 0415.680.335
Antwerpen · FTE 1.1
APOTHEEK SCARPHOUT
BE 0421.970.586
Blankenberge · FTE 1.1
Of 5,220 companies in sector 47730 we hold annual accounts for 3,862. 2,288 are within a factor 10 of this headcount. The 5 above are the closest to it. See the whole sector
Identification & contact
Identification
Legal formPrivate limited company
Founded07-10-1991
Fiscal year end31-12
Abbreviation FR
Paracity
Activities, NACEBEL 2025
20140Manufacture of chemicals and chemical products
47730Retail sale of pharmaceutical products
E-invoicing
Reachable via Peppol
Peppol ID
0208:0445338678
Also
9925:BE0445338678
Registered
15-10-2025
The company is no longer active; its Peppol card can remain until its access point withdraws it.
Register as of 28 September 2026 · Peppol Directory
Scores and ratios are computed by Checked and are not a credit decision.